Skip navigation

In this issue...

Innovation – the centre of corporate strategiese
Lord Sainsbury, UK Minister for Science and Innovation
British Innovations
On the road again
Christopher Macgowan, Chief Executive, Society of Motor Manufacturers and Traders
Fossil Fuels – An Energy source for the Future
Greg Lewin, President, Shell Global Solutions
Chain of success
Kenny McKay, Director, and Will Wright, Manager, Restructuring practice at KPMG
Innovation and the Patent Office
Lawrence Smith-Higgins, Head of Awareness Information & Media The UK Patent Office
Benefits of association
Dr Michael Moore, CEO, PIramed Ltd
Innovation and strength in the UK biotech sector
Aisling Burnand, Chief Executive, BioIndustry Association
Simfonec: Helping make good research BIG business
Heron Evidence Development: Successful deal of missed opportunity
Springwell Ltd: Match-maker for Innovative Technologies
Korn/Ferry International: Pharmaceutical companies desire to break the mould
A quality core interface
Dominique Kleyn head of BioPharma Business Development, Imperial College London
Evolutec Group: Creating a range of commercial options
Moving forward
Dr Ceri Williams, Senior Manager, Science and Innovation at Yorkshire Forward and Dr Danielle Hankin, Bioscience Cluster Manager
Oxitech: Revolutionising SIT Programmes
Oxford Expression Technologies: Meeting the needs of the post-genomic era
Business Services
Innovating business related services
Norma Rose, Director-General, Business Services Association
BT: Innovation Strategy and Innovation Continuum
UK Film Council: How the UK wins in the international film industry?
On the defence
Major General Alan Sharman CBE, Director General, Defence Manufacturers Association
ProEtch: Precision parts of quality
Wallop Defence Systems: Aircraft Countermeasures and the Dual Spectral Threat
Education, Education, Education
Ruth Kelly, Secretary of State for Education and Skills
Applied Sciences at Wolverhampton - Innovation in Higher Education Professor Trevor Hocking, Associate Dean, International Development
Wind energy
Marus Rand, Chief Executive, British Wind Energy Association
Vital energy
Ian Leitch, Commercial Director, Energy Industries Council
Waterman Group: Solutions to solve climate control legislation
Winning the war against germs
Dr Ron Mitchell, Managing Director, GB Environmental
Show me the money! Funding for innovation – who can help?
UK: Innovation Nation?
Launching the “Innovation Nation?” initiative
Innovation in the 21st Century
Gemma Harman, Director of Strategy & Media, BT Chief Technology Office
UK Manufacturing - a driving force for innovation
Andrew Manly, Director General, Manufacturing Technologies Association
Waterman Group: Single project model 3D
Renishaw: Achieving global manufacturing competitiveness in the UK
Yorkshire Forward
The European Nanotechnology Trade Alliance
Del Stark, Chief Executive, European Nanotechnology Trade Alliance
University research drives a new wave of innovation
Omar Cheema, Nanotechnology Business Development, Imperial College London
Oxford Instruments: Enabling nanoscience and nanotechnology
Semefab (Scotland): A real driver of change
Metal Nanopowders: New products that meet your needs
Regional Development
London Development Agency: One jump ahead
91Advantage West Midlands: At the heart of it all 95


Successful deal of
missed opportunity

Innovative research and a supply of leading scientists have generated a world-renowned biotech hub in the UK. This technological innovation has also contributed to a growing Health Technology Assessment (HTA) community worldwide. HTA groups provide help to health services around the world by analysing the evidence that underpins therapies and making recommendations on which products should be used. Biotech is not the only area of excellence in healthcare innovation in the UK. Agencies such as the National Institute for Health and Clinical Excellence (NICE) and its advisers are also at the forefront of the global HTA system. The most successful biotech companies have combined innovative science with a willingness to develop the evidence demanded by HTA groups to provide patients with accelerated access to effective, novel treatments.

As biotech companies and health services are acutely aware, the money that enables scientific innovation is not endless. Difficult decisions have to be made by healthservice managers to ensure that scarce resources for healthcare are spent on the technologies that are proven to be effective. Healthcare resourcing decisions are informed by five main pieces of evidence: Biotech companies rightly concentrate research effort on answering the first three of these questions; the questions asked by industry regulators. The most farsighted companies also address the final two questions; those asked by the HTA advisers to healthcare reimbursement agencies.

The demands for high-quality evidence from regulatory and reimbursement authorities are stringent. It is no coincidence that investors in biotech, be they pharmaceutical partners or venture capital fund managers, make similar demands. The ability to meet all these demands, through addressing all five questions, can make the difference between a successful deal and a missed opportunity ? the most sophisticated biotech companies have gained a competitive edge when entering investment or partnering discussions with robust answers to all five.

The UK biotech industry continues to thrive, not only because it attracts world-class scientists, but also because it has access to world-leading HTA experts. Putting a value on innovation is no longer simply desirable ? it is essential. The UK biotech industry is well-placed to make use of the wealth of UK HTA expertise to support its scientific innovation and to continue developing valuable therapies.

Paul Howard

Paul is a co-founder of Heron Evidence Development Ltd ( Heron has been working with biotech and pharmaceutical companies since 1999 to demonstrate the value of innovative products to the reimbursement community. Heron is situated near Cambridge, UK. If you are aspiring to a biotech deal, and would like to learn more about how HTA principles could add benefit, we will be pleased to hear from you.